histone H3.3-K27M targeted neoantigen vaccine therapy (TCRCure Biopharma)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namehistone H3.3-K27M targeted neoantigen vaccine therapy (TCRCure Biopharma)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptideVaccines > Application > Therapeutic vaccine
Mechanisms of ActionHuman leukocyte antigen modulators
TargetsHuman leukocyte antigen
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTcrcure Biopharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTcrcure Biopharma Ltd
Inactive CompaniesN/A
Active IndicationsGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A